About Celator

CELATOR^® is a privately held biopharmaceutical company working to develop new and more effective combination therapies to treat cancer.

CombiPlex^SM/TM, the company’s drug ratio technology platform, represents a revolutionary new approach to the development of combination therapies. Based on the strength of the CombiPlex technology platform, Celator is positioned to develop a range of products targeting many different forms of cancer. The Company’s development program already includes several promising combination therapy product candidates:

• CPX-1 (Irinotecan HCI-Floxuridine ) is in Phase 2 clinical development as a treatment for colorectal cancer. Click here (www.clinicaltrials.gov) for more information on the Phase 2 study. Click here (CPX-1 ASCO Poster Presentation) to see Celator's recent report of results from Phase 1 clinical trials for CPX-1.
• CPX-351 (Cytarabine-Daunorubicin) is in Phase 1 clinical development as a treatment for acute myeloid leukemia (AML). Click here (www.clinicaltrials.gov) for more information on the Phase 1 study.
• Other combinations are in preclinical evaluation as therapy options for a range of cancers.
• Click here (EORTC Poster Presentation) to see a report on the potential benefit of
  ratiometric dosing.

Celator is led by a management team with extensive experience in all phases of pharmaceutical product development and clinical research. While the company’s current focus is in oncology, early stage research has also shown that the CombiPlex platform could be applied to other diseases.

Celator’s Technology Advantage

Many forms of cancer are treated with regimens that combine different chemotherapeutic agents. Because individual chemotherapeutic agents are toxic at certain levels, these “cocktails” are typically developed by combining drugs that have non-overlapping toxicity profiles. In this way, individual agents can be combined at maximum dosing levels. This approach has represented the standard of care in oncology for many years.

By focusing only on the impact of individual agents, this standard has failed to recognize the critical role that drug ratios can play in the effectiveness of combination chemotherapies. Research efforts led by Celator have shown that individual chemotherapeutic agents can interact synergistically when combined at certain ratios. At other ratios the combinations can be antagonistic. Thus, the ratio of drugs used to create these regimens – and the ability to control that ratio systemically – can have a profound impact on their overall efficacy.

Based on this essential understanding, Celator has developed a proprietary drug combination platform, CombiPlex, which has shown significant promise in identifying and delivering optimal drug ratios for combination therapies. With this technology advantage, Celator is positioned to develop an expansive pipeline of new combination chemotherapies with the potential of enhanced efficacy.

The Company currently has numerous patent applications pending worldwide. These patents cover the CombiPlex platform and applications related to products developed using Celator’s drug combination carrier technology. Others provide coverage related to technology extending from lipid-based carrier formulation techniques through to novel peptide, polymer and lipid-polymer hybrid technologies.

Celator’s Business Strategy

Celator is developing a range of promising product opportunities based on the applications of the CombiPlex technology platform. Initially, the company is targeting combination therapies involving agents already approved and widely used to treat cancer. This approach positions Celator to pursue multiple product opportunities involving known therapeutic agents.

The CombiPlex technology platform has the potential to be applied to numerous new product opportunities. Future targets will include product candidates based on new combinations of existing drugs as well as combinations derived from new drug agents. If successful, the current standards in development of combination therapies based solely on tolerability will be replaced. Celator will help to introduce a new medical standard in the development of combination therapies based on the ability to identify and control drug ratios and synergies.

Within this framework, Celator will focus on a business strategy designed to maximize the -potential of the CombiPlex technology platform, including:

• commercialization through internal development, strategic partnering or out-licensing;
• collaborations with leading research centers in oncology and other areas; and
• pursuit of broad patent and intellectual property protection